Immune Therapy for Liver Cancers

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor prognosis with 5-year overall survival rates around 15%, all stages taken together. These primary liver malignancies are often diagnosed at advanced stages where therapeutic options are limited. Recently, immune therapy ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilmi, Marc, Vienot, Angélique, Rousseau, Benoît, Neuzillet, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016834/
https://www.ncbi.nlm.nih.gov/pubmed/31892230
http://dx.doi.org/10.3390/cancers12010077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016834/
https://www.ncbi.nlm.nih.gov/pubmed/31892230
http://dx.doi.org/10.3390/cancers12010077

Ejemplares similares